Please login to the form below
advanced breast cancer
This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.
Tecentriq combo fails in advanced triple negative breast cancer
Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... TNBC is an aggressive and hard-to-treat
Latest news
-
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
It will become available for patients across England who have hormone receptor-positive, HER2-negative, advanced breast cancer who have already had endocrine therapy. ... Ibrance is already available via the CDF as a second-line breast cancer treatment
-
AZ, Merck win FDA approval for Lynparza in pancreatic cancer
Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer,” he added. ... Lynparza is already approved as a treatment for ovarian, fallopian tube, primary pertioneal and BRCA-mutated
-
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
After three years’ follow-up, around 88% of people treated with Kadcyla did not have their breast cancer return, compared to 77% of the Herceptin group. ... Among the rivals is Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan (DS-8201),
-
AZ, Daiichi Sankyo strengthen case for HER2 candidate
The phase 2 Destiny-Breast01 study investigated trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients, who had already received two or more prior HER2-targeting therapies. ... These results are impressive, as women with this advanced
-
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
It originally scored approval in the EU in November 2016, for the treatments of hormone receptor positive, HER-2 negative, locally advanced metastatic breast cancer. ... However, it then re-considered its decision after Pfizer submitted an ‘improved
More from news
Approximately 1 fully matching, plus 154 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
advanced or refractory HER2-positive metastatic breast cancer, DS-8201 was recently approved by the FDA with the brand name Enhertu for the treatment of adult patients with unresectable or metastatic ... HER2 positive breast cancer who have received two
-
Leading AstraZeneca’s return to growth in Europe
The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in
-
The handover: Pfizer reshapes itself for a new era
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Digital disruption
Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Battling breast cancer with precision medicine (Part 1)
She told me I had advanced breast cancer and urged me to drive down to the local emergency room immediately to get additional tests and start chemotherapy that weekend. ... I was diagnosed with inflammatory breast cancer (IBC) with axillary lymph node
-
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy
-
Indigenus agencies honoured at 2012 Globals, CLIOs and Rx Club Awards
The Fight Forward campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories for the agency.
-
Indigenus Agencies Claim Honors at 2012 Globals, CLIOs, Rx Club Awards
The “Fight Forward” campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Russia becomes first country to approve a COVID-19 vaccine
- Tecentriq combo fails in advanced triple negative breast cancer
- UK agrees on COVID-19 vaccine deals with J&J and Novavax
- COVID-19 vaccine approval unlikely before November, says US NIH director
- Calliditas bets on PBC drug in Genkyotex buyout
- Emotion-driven clinical trial marketing: A missed opportunity?
- Speed kills
- Unleashing the Potential of Multichannel Digital Strategies in Healthcare
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Emotion-driven clinical trial marketing: A missed opportunity?
- Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Quick links
Infographics
